Predicta Biosciences is a precision oncology company that leverages cutting-edge multiomics and artificial intelligence (AI) to develop innovative diagnostic and therapeutic products. The company operates in the healthcare sector, specifically focusing on oncology, and serves healthcare providers and payers. Predicta Biosciences' core business model revolves around creating diagnostic solutions that ensure patients receive optimal therapy throughout their treatment journey. By utilizing small blood-based samples, the company provides clear and actionable data to determine whether patients will respond to specific treatments, thereby eliminating the need for invasive bone marrow biopsies. Predicta Biosciences generates revenue through the sale of its diagnostic tests and data-driven insights to healthcare providers and payers. The company's platform also fuels a vast database, which is mined using AI tools to discover novel therapeutic targets, further enhancing its product offerings. Predicta Biosciences empowers clinicians with the necessary tools and knowledge to make informed decisions, ultimately aiming to improve patient outcomes.

Keywords: precision oncology, multiomics, AI, diagnostic solutions, therapeutic products, healthcare providers, payers, blood-based samples, patient care, data-driven insights.